Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000160

Drug Information
NameLevofloxacin
Synonyms(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Cravit Ophthalmic; SMR000466387; Ofloxacin S-(-)-form; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; RWJ-25213; LEVOFLOXACIN; Spectrum3_000995; R-Ofloxacin; DR3355; CCRIS 4073; HR-355; Volequin; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; DR-3355: L-isomer of ofloxacin; KBioGR_001605; SAM001246758; HMS1922J07; Oftaquix; Leroxacin; MolPort-002-885-835; LS-133260; Spectrum4_001123; Nofaxin; Spectrum_001719; (−)-Ofloxacin; MLS001165709; Cravit (TN); KBio3_001909; Floxacin; LFX; Levofloxacin tablet, suspension or intravenous; NCGC00178529-01; KBio2_007335; AC-7593; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Aeroquin; C18H20FN3O4.H2O; 100986-85-4; (-)-Ofloxacin; C07660; Levox; KBio2_004767; Levoxacin; 28266_FLUKA; Levofloxacine; Floxel; CHEMBL33; 100986-86-5; MLS001423977; Levofloxacinum; KBioSS_002199; DR-3355; Mosardal; Spectrum5_001438; Levofloxacino [INN-Spanish]; C18H20FN3O4; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; L0193; Levofloxacin [USAN:INN:JAN]; KBio2_002199; HMS2090O10; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; 28266_SIGMA; Levofloxacine [INN-French]; Iquix; Reskuin; BRD-K09471561-001-06-7; Levokacin; Lesacin; (R)-isomer; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-; CID149096; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-; CPD000466387; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hemihydrate, (S)-; LS-171761; AC1L3YF8; Spectrum2_001676; HMS2051G04; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; Cravit; (S)-(-)-Ofloxacin; Levaquin; S1940_Selleck; SPBio_001891; Levofloxacinum [INN-Latin]; HMS2093E18; (S)-Ofloxacin; LVX; Levofloxacin (INN); MP-376; DR 3354; HR 355; BSPBio_002689; Quixin; MLS000759524; SPECTRUM1504260; Elequine; D08120; S-(-)-Ofloxacin; d-Levofloxacin; Ambap100986-85-4; DB01137; Tavanic; RWJ 25213-097; L-Ofloxacin; Levofloxacino; CCRIS 4074
Trade NameLevaquin; Tavanic; Oftaquix; Quixin; Iquix
CompanySanofi-Aventis
IndicationBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7
-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/
t10-/m0/s1
InChIKeyGSDSWSVVBLHKDQ-JTQLQIEISA-N
Canonical SMILESCC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O    
Isomeric SMILESC[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Therapeutic ClassAnti-Bacterial Agents
CAS NumberCAS 100986-85-4
FormulaC18H20FN3O4
PubChem Compound IDCID 149096.
PubChem Substance IDSID 9862.
SuperDrug ATC IDJ01MA12; S01AE05
SuperDrug CAS ID100986854;
TargetDNA topoisomerase IIInhibitor[2]
DNA topoisomerase IIMultitarget[2]
Topoisomerase IVInhibitor[2]
Topoisomerase IVMultitarget[2]
Ref 1How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. To Reference
Ref 2DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543